Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | CA12 | O43570 | 4/20 | 0.60 |
| ▸ | CA1 | P00915 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.60 |
| ▸ | CA9 | Q16790 | 4/20 | 0.60 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113855 | 0.86 | RAB9A (0.79) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL17316258 | 0.85 | RAB9A (0.59) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL172035 | 0.82 | CA2 (0.64) | CA2KMT2ATP53AKR1C3PTGS2 | |
| SCHEMBL9913187 | 0.81 | PTGS2 (0.72) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL12793734 | 0.81 | PTGS2 (0.72) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL22187348 | 0.80 | ENPP1 (0.58) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL12224808 | 0.80 | MEN1 (0.63) | RAB9AKMT2AMEN1POLBGAA | |
| SCHEMBL4113545 | 0.80 | MAPT (0.68) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL4920494 | 0.79 | PTGS2 (0.73) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL12049668 | 0.79 | KMT2A (0.71) | KMT2ATGM2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | RAB9A 815/4885CA12 4452/4885CA1 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.